Nasipral (Ipratropium Bromide)

Ipratropium bromide blocks muscarinic acetylcholine receptors on the nasal mucosa. This competitive antagonism prevents the parasympathetic signals that normally stimulate glandular secretions and blood vessel dilation, thereby decreasing nasal mucus production and reducing swelling.

The appropriate dose of Nasipral is determined by the prescribing clinician based on the patient’s age, severity of symptoms and overall health. Healthcare providers select the number of sprays per nostril and frequency according to established clinical guidelines.

Safety data for ipratropium bromide in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare professional before using Nasipral.

To request Nasipral, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike topical sympathomimetic decongestants such as oxymetazoline, Nasipral (ipratropium bromide) is an anticholinergic that primarily reduces secretions rather than causing vasoconstriction. This mechanism can result in fewer rebound congestion effects, making it suitable for longer‑term or repeated use under medical supervision.

Nasipral should be stored at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, heat and direct sunlight, and ensure the container is tightly closed when not in use.

Nasipral is administered intranasally. The patient tilts the head slightly forward, inserts the spray tip into one nostril, and gently presses the actuator to deliver the prescribed number of sprays. The same procedure is repeated in the other nostril if directed by the prescriber.

Serious adverse reactions, although rare, include allergic responses such as rash, swelling, angioedema, severe nasal ulceration, and paradoxical bronchospasm. Patients should seek immediate medical attention if they experience difficulty breathing, facial swelling or any signs of anaphylaxis.

Nasipral should be avoided in individuals with known hypersensitivity to ipratropium bromide or other anticholinergic agents. Caution is also advised for patients with narrow‑angle glaucoma, urinary retention, or severe nasal obstruction, and it should only be used under medical guidance in these cases.